These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29597002)

  • 1. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
    Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
    J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
    Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
    J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
    Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
    Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
    Boyiadzis M; Agha M; Redner RL; Sehgal A; Im A; Hou JZ; Farah R; Dorritie KA; Raptis A; Lim SH; Wang H; Lapteva N; Mei Z; Butterfield LH; Rooney CM; Whiteside TL
    Cytotherapy; 2017 Oct; 19(10):1225-1232. PubMed ID: 28864289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.
    Kottaridis PD; North J; Tsirogianni M; Marden C; Samuel ER; Jide-Banwo S; Grace S; Lowdell MW
    PLoS One; 2015; 10(6):e0123416. PubMed ID: 26062124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with double-bright (CD56
    Silla L; Valim V; Pezzi A; da Silva M; Wilke I; Nobrega J; Vargas A; Amorin B; Correa B; Zambonato B; Scherer F; Merzoni J; Sekine L; Huls H; Cooper LJ; Paz A; Lee DA
    Br J Haematol; 2021 Dec; 195(5):710-721. PubMed ID: 34490616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
    Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
    Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
    Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
    Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
    [No Abstract]   [Full Text] [Related]  

  • 13. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
    Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
    Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia - a summary.
    Zhang X; Yang J; Zhang G; Song L; Su Y; Shi Y; Zhang M; He J; Song D; Lv F; Wu P; Wang H; Wang T; Zhang Y; Liu H; Lu P
    Immunotherapy; 2020 Jan; 12(1):63-74. PubMed ID: 31914839
    [No Abstract]   [Full Text] [Related]  

  • 15. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
    Parisi S; Ruggeri L; Dan E; Rizzi S; Sinigaglia B; Ocadlikova D; Bontadini A; Giudice V; Urbani E; Ciardelli S; Sartor C; Cristiano G; Nanni J; Zannoni L; Chirumbolo G; Arpinati M; Lewis RE; Bonifazi F; Marconi G; Martinelli G; Papayannidis C; Paolini S; Velardi A; Cavo M; Lemoli RM; Curti A
    Front Immunol; 2021; 12():804988. PubMed ID: 35173709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
    Meazza R; Ruggeri L; Guolo F; Minetto P; Canevali P; Loiacono F; Ciardelli S; Bo A; Luchetti S; Serio A; Zannoni L; Retière C; Colomar-Carando N; Parisi S; Curti A; Lemoli RM; Pende D
    Front Immunol; 2023; 14():1111419. PubMed ID: 36865545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Kang YL; Lee JH; Lee JH; Kim DY; Lee JL; Park HS; Choi EJ; Lee YS; Kang YA; Jeon M; Seol M; Baek S; Yun SC; Kim HJ; Lee KH
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2065-2076. PubMed ID: 27530969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
    Otegbeye F; Cooper B; Caimi P; Zamborsky K; Reese-Koc J; Hillian A; Hernandez-Collazo Y; Lee G; Boughan K; Tomlinson B; Gallogly M; Metheny L; Bajor D; Selfridge J; Saltzman J; Lazarus H; de Lima M; Wald D
    Transplant Cell Ther; 2022 May; 28(5):250.e1-250.e8. PubMed ID: 35172204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia.
    Kulkarni U; Arunachalam AK; Palani HK; Nair RR; Balasundaram N; Venkatraman A; Korula A; Selvarajan S; Lionel S; Balasubramanian P; Maddali M; Abraham A; George B; Mathews V
    Cell Transplant; 2023; 32():9636897231198178. PubMed ID: 37706453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.